Symbols / AFMDQ $0.00 +0.00% Affimed N.V.
AFMDQ Chart
About
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.28K |
| Enterprise Value | -11.21M | Income | -69.97M | Sales | 5.64M |
| Book/sh | 1.21 | Cash/sh | 1.47 | Dividend Yield | — |
| Payout | 0.00% | Employees | 76 | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | 0.00 | P/B | 0.00 | P/C | — |
| EV/EBITDA | 0.18 | EV/Sales | -1.99 | Quick Ratio | 1.71 |
| Current Ratio | 1.93 | Debt/Eq | 74.96 | LT Debt/Eq | — |
| EPS (ttm) | -5.27 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | -91.60% | Earnings | 2024-11-14 06:00 | ROA | -49.42% |
| ROE | -149.49% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -87.09% | Profit Margin | 0.00% | Shs Outstand | 16.39M |
| Shs Float | 15.48M | Short Float | 3.75% | Short Ratio | 4.60 |
| Short Interest | — | 52W High | 1.13 | 52W Low | 0.00 |
| Beta | 0.84 | Avg Volume | 2.72K | Volume | 2.60K |
| Target Price | — | Recom | None | Prev Close | $0.00 |
| Price | $0.00 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-49.84
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-05-14 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2025-05-13 | down | Wells Fargo | Overweight → Equal-Weight | $0 |
| 2025-05-13 | down | Leerink Partners | Outperform → Market Perform | $0 |
| 2024-12-12 | main | Wells Fargo | Overweight → Overweight | $15 |
| 2024-12-10 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
- Affimed N.V. (AFMDQ) Stock Price, News, Quote & History - ca.finance.yahoo.com Sun, 25 May 2025 17
- Why Is Affimed N.V. (AFMDQ) Stock Up Today? - Meyka Mon, 30 Mar 2026 02
- What is the current Price Target and Forecast for Affimed (AFMDQ) - zacks.com Sat, 28 Jun 2025 13
- Affimed shares to be delisted from Nasdaq after insolvency filing - Investing.com Wed, 14 May 2025 07
- Affimed stock gains on FDA fast track tag for lymphoma drug (NASDAQ:AFMD) - Seeking Alpha ue, 12 Sep 2023 07
- Affimed stock wins FDA nod to study lymphoma candidate - Seeking Alpha ue, 23 May 2023 07
- Affimed NV (AFMD) Stock Forecast & Price Prediction 2026–2030 - CoinCodex Mon, 15 Mar 2021 10
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue |
|
8.28
-79.99%
|
41.35
+2.45%
|
40.37
|
| Operating Revenue |
|
8.28
-79.99%
|
41.35
+2.45%
|
40.37
|
| Operating Expense |
|
119.41
-8.37%
|
130.33
+23.69%
|
105.36
|
| Research And Development |
|
94.96
-3.90%
|
98.81
+21.26%
|
81.49
|
| Selling General And Administration |
|
24.68
-23.07%
|
32.08
+32.44%
|
24.22
|
| General And Administrative Expense |
|
24.68
-23.07%
|
32.08
+32.44%
|
24.22
|
| Salaries And Wages |
|
13.05
-14.39%
|
15.25
+42.34%
|
10.71
|
| Other Gand A |
|
8.82
-33.85%
|
13.33
+22.41%
|
10.89
|
| Other Operating Expenses |
|
-0.22
+60.92%
|
-0.56
-63.66%
|
-0.34
|
| Total Expenses |
|
119.41
-8.37%
|
130.33
+23.69%
|
105.36
|
| Operating Income |
|
-111.14
-24.91%
|
-88.97
-36.89%
|
-65.00
|
| Total Operating Income As Reported |
|
-106.66
-21.04%
|
-88.12
-37.62%
|
-64.03
|
| EBITDA |
|
-102.38
-25.66%
|
-81.47
-46.86%
|
-55.48
|
| Normalized EBITDA |
|
-103.81
-22.48%
|
-84.76
-34.04%
|
-63.24
|
| Reconciled Depreciation |
|
1.75
-39.67%
|
2.90
+117.32%
|
1.33
|
| EBIT |
|
-104.13
-23.42%
|
-84.37
-48.52%
|
-56.81
|
| Total Unusual Items |
|
1.43
-56.50%
|
3.29
-57.65%
|
7.76
|
| Total Unusual Items Excluding Goodwill |
|
1.43
-56.50%
|
3.29
-57.65%
|
7.76
|
| Net Income |
|
-105.94
-23.18%
|
-86.00
-49.51%
|
-57.52
|
| Pretax Income |
|
-105.94
-23.18%
|
-86.00
-49.51%
|
-57.52
|
| Net Non Operating Interest Income Expense |
|
0.24
+118.75%
|
-1.27
-12.60%
|
-1.13
|
| Interest Expense Non Operating |
|
1.81
+10.80%
|
1.63
+128.93%
|
0.71
|
| Net Interest Income |
|
0.24
+118.75%
|
-1.27
-12.60%
|
-1.13
|
| Interest Expense |
|
1.81
+10.80%
|
1.63
+128.93%
|
0.71
|
| Interest Income Non Operating |
|
0.51
|
0.00
|
0.00
|
| Interest Income |
|
0.51
|
0.00
|
0.00
|
| Other Income Expense |
|
4.96
+17.10%
|
4.24
-50.71%
|
8.60
|
| Other Non Operating Income Expenses |
|
3.54
+270.93%
|
0.95
+13.32%
|
0.84
|
| Gain On Sale Of Security |
|
1.43
-56.50%
|
3.29
-57.65%
|
7.76
|
| Tax Provision |
|
0.00
+50.00%
|
0.00
+0.00%
|
0.00
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
-22.22%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.30
-56.50%
|
0.69
-67.06%
|
2.10
|
| Net Income Including Noncontrolling Interests |
|
-105.94
-23.18%
|
-86.00
-49.51%
|
-57.52
|
| Net Income From Continuing Operation Net Minority Interest |
|
-105.94
-23.18%
|
-86.00
-49.51%
|
-57.52
|
| Net Income From Continuing And Discontinued Operation |
|
-105.94
-23.18%
|
-86.00
-49.51%
|
-57.52
|
| Net Income Continuous Operations |
|
-105.94
-23.18%
|
-86.00
-49.51%
|
-57.52
|
| Normalized Income |
|
-107.07
-20.84%
|
-88.60
-40.22%
|
-63.19
|
| Net Income Common Stockholders |
|
-105.94
-23.18%
|
-86.00
-49.51%
|
-57.52
|
| Diluted EPS |
|
-7.09
-18.17%
|
-6.00
-25.00%
|
-4.80
|
| Basic EPS |
|
-7.09
-18.17%
|
-6.00
-25.00%
|
-4.80
|
| Basic Average Shares |
|
14.94
+4.94%
|
14.24
+19.13%
|
11.95
|
| Diluted Average Shares |
|
14.94
+4.94%
|
14.24
+19.13%
|
11.95
|
| Diluted NI Availto Com Stockholders |
|
-105.94
-23.18%
|
-86.00
-49.51%
|
-57.52
|
| Insurance And Claims |
|
2.80
-19.84%
|
3.49
+33.68%
|
2.61
|
| Total Other Finance Cost |
|
-1.53
-325.21%
|
-0.36
-186.99%
|
0.41
|
| Line Item | Trend | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Assets |
|
97.16
-51.55%
|
200.51
-10.94%
|
225.13
|
| Current Assets |
|
84.19
-57.06%
|
196.07
-5.00%
|
206.39
|
| Cash Cash Equivalents And Short Term Investments |
|
72.90
-61.69%
|
190.29
-3.72%
|
197.63
|
| Cash And Cash Equivalents |
|
38.53
-79.75%
|
190.29
-3.72%
|
197.63
|
| Cash Equivalents |
|
11.90
|
0.00
|
—
|
| Cash Financial |
|
26.63
-86.01%
|
190.29
|
—
|
| Other Short Term Investments |
|
34.37
|
0.00
|
—
|
| Receivables |
|
5.33
+97.52%
|
2.70
-43.92%
|
4.81
|
| Accounts Receivable |
|
5.33
+97.52%
|
2.70
-43.92%
|
4.81
|
| Inventory |
|
0.46
-26.27%
|
0.63
+49.17%
|
0.42
|
| Other Current Assets |
|
5.50
+123.67%
|
2.46
-30.42%
|
3.53
|
| Total Non Current Assets |
|
12.97
+191.96%
|
4.44
-76.30%
|
18.74
|
| Net PPE |
|
12.94
+195.26%
|
4.38
-8.40%
|
4.79
|
| Gross PPE |
|
16.03
+86.05%
|
8.61
+2.95%
|
8.37
|
| Accumulated Depreciation |
|
-3.08
+27.14%
|
-4.23
-18.12%
|
-3.58
|
| Properties |
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
8.04
+1372.34%
|
0.55
|
—
|
| Machinery Furniture Equipment |
|
7.93
-0.74%
|
7.99
+9.19%
|
7.32
|
| Other Properties |
|
—
|
0.56
-42.28%
|
0.97
|
| Leases |
|
0.05
-29.73%
|
0.07
+0.00%
|
0.07
|
| Goodwill And Other Intangible Assets |
|
0.03
-56.90%
|
0.06
-96.39%
|
1.61
|
| Other Intangible Assets |
|
0.03
-56.90%
|
0.06
-96.39%
|
1.61
|
| Investments And Advances |
|
—
|
0.00
-100.00%
|
12.35
|
| Total Liabilities Net Minority Interest |
|
39.35
-17.33%
|
47.60
-46.63%
|
89.18
|
| Current Liabilities |
|
25.91
-25.23%
|
34.65
-46.32%
|
64.55
|
| Payables And Accrued Expenses |
|
18.92
-0.84%
|
19.08
+1.15%
|
18.86
|
| Payables |
|
18.92
-0.84%
|
19.08
+1.15%
|
18.86
|
| Accounts Payable |
|
18.92
-0.84%
|
19.08
+1.15%
|
18.86
|
| Current Debt And Capital Lease Obligation |
|
6.37
+0.73%
|
6.33
+400.87%
|
1.26
|
| Current Debt |
|
5.83
-1.64%
|
5.93
+922.41%
|
0.58
|
| Other Current Borrowings |
|
5.83
-1.64%
|
5.93
+922.41%
|
0.58
|
| Current Capital Lease Obligation |
|
0.54
+36.11%
|
0.40
-42.02%
|
0.68
|
| Current Deferred Liabilities |
|
0.62
-93.31%
|
9.25
-79.18%
|
44.42
|
| Current Deferred Revenue |
|
0.62
-93.31%
|
9.25
-79.18%
|
44.42
|
| Total Non Current Liabilities Net Minority Interest |
|
13.44
+3.84%
|
12.95
-47.45%
|
24.64
|
| Long Term Debt And Capital Lease Obligation |
|
12.98
+9.41%
|
11.86
-31.93%
|
17.43
|
| Long Term Debt |
|
6.32
-45.93%
|
11.69
-31.49%
|
17.06
|
| Long Term Capital Lease Obligation |
|
6.66
+3684.09%
|
0.18
-52.17%
|
0.37
|
| Non Current Deferred Liabilities |
|
0.46
-57.16%
|
1.08
-84.98%
|
7.21
|
| Non Current Deferred Revenue |
|
0.46
-57.16%
|
1.08
-84.98%
|
7.21
|
| Stockholders Equity |
|
57.81
-62.20%
|
152.91
+12.48%
|
135.95
|
| Common Stock Equity |
|
57.81
-62.20%
|
152.91
+12.48%
|
135.95
|
| Capital Stock |
|
1.50
+0.47%
|
1.49
+20.99%
|
1.23
|
| Common Stock |
|
1.50
+0.47%
|
1.49
+20.99%
|
1.23
|
| Share Issued |
|
15.00
+0.43%
|
14.93
+21.00%
|
12.34
|
| Ordinary Shares Number |
|
15.00
+0.43%
|
14.93
+21.00%
|
12.34
|
| Retained Earnings |
|
-536.13
-24.63%
|
-430.19
-29.03%
|
-333.40
|
| Gains Losses Not Affecting Retained Earnings |
|
592.43
+1.86%
|
581.61
+24.25%
|
468.11
|
| Other Equity Adjustments |
|
592.43
+1.86%
|
581.61
+24.25%
|
468.11
|
| Total Equity Gross Minority Interest |
|
57.81
-62.20%
|
152.91
+12.48%
|
135.95
|
| Total Capitalization |
|
64.13
-61.04%
|
164.60
+7.58%
|
153.01
|
| Working Capital |
|
58.28
-63.89%
|
161.42
+13.80%
|
141.85
|
| Invested Capital |
|
69.96
-58.98%
|
170.53
+11.03%
|
153.59
|
| Total Debt |
|
19.35
+6.39%
|
18.19
-2.69%
|
18.69
|
| Capital Lease Obligations |
|
7.20
+1158.57%
|
0.57
-45.58%
|
1.05
|
| Net Tangible Assets |
|
57.78
-62.20%
|
152.86
+13.78%
|
134.34
|
| Tangible Book Value |
|
57.78
-62.20%
|
152.86
+13.78%
|
134.34
|
| Investmentin Financial Assets |
|
—
|
0.00
-100.00%
|
12.35
|
| Line Item | Trend | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow |
|
-110.27
-5.13%
|
-104.89
-21.13%
|
-86.59
|
| Cash Flow From Continuing Operating Activities |
|
-110.27
-5.13%
|
-104.89
-21.13%
|
-86.59
|
| Net Income From Continuing Operations |
|
-105.94
-23.18%
|
-86.00
-49.51%
|
-57.52
|
| Depreciation Amortization Depletion |
|
1.75
-39.67%
|
2.90
+117.32%
|
1.33
|
| Depreciation |
|
1.72
|
—
|
—
|
| Amortization Cash Flow |
|
0.03
|
—
|
—
|
| Depreciation And Amortization |
|
1.75
-39.67%
|
2.90
+117.32%
|
1.33
|
| Amortization Of Intangibles |
|
0.03
|
—
|
—
|
| Other Non Cash Items |
|
-0.73
+65.71%
|
-2.12
+67.48%
|
-6.51
|
| Stock Based Compensation |
|
10.71
-43.94%
|
19.11
+61.68%
|
11.82
|
| Deferred Tax |
|
0.00
+50.00%
|
0.00
+0.00%
|
0.00
|
| Deferred Income Tax |
|
0.00
+50.00%
|
0.00
+0.00%
|
0.00
|
| Operating Gains Losses |
|
-4.26
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
0.08
|
0.00
|
0.00
|
| Change In Working Capital |
|
-12.16
+68.05%
|
-38.07
-9.36%
|
-34.81
|
| Change In Receivables |
|
1.09
-48.27%
|
2.11
+189.19%
|
-2.37
|
| Change In Inventory |
|
0.10
+148.31%
|
-0.21
-18.29%
|
-0.17
|
| Change In Payables And Accrued Expense |
|
-9.77
+76.21%
|
-41.05
-36.87%
|
-29.99
|
| Change In Payable |
|
-9.77
+76.21%
|
-41.05
-36.87%
|
-29.99
|
| Change In Account Payable |
|
-9.77
+76.21%
|
-41.05
-36.87%
|
-29.99
|
| Change In Other Current Assets |
|
-3.59
-433.77%
|
1.07
+147.27%
|
-2.27
|
| Investing Cash Flow |
|
-36.06
-743.34%
|
5.61
+245.58%
|
-3.85
|
| Cash Flow From Continuing Investing Activities |
|
-36.06
-743.34%
|
5.61
+245.58%
|
-3.85
|
| Net PPE Purchase And Sale |
|
-3.73
-465.86%
|
-0.66
+69.99%
|
-2.20
|
| Purchase Of PPE |
|
-3.73
-465.86%
|
-0.66
+69.99%
|
-2.20
|
| Capital Expenditure |
|
-3.73
-435.78%
|
-0.70
+81.92%
|
-3.85
|
| Net Investment Purchase And Sale |
|
-33.31
-628.61%
|
6.30
|
0.00
|
| Purchase Of Investment |
|
-34.25
|
0.00
|
0.00
|
| Sale Of Investment |
|
0.94
-85.11%
|
6.30
|
0.00
|
| Net Business Purchase And Sale |
|
0.98
|
0.00
|
0.00
|
| Gain Loss On Sale Of Business |
|
-4.34
|
0.00
|
0.00
|
| Net Intangibles Purchase And Sale |
|
0.00
+100.00%
|
-0.04
+97.76%
|
-1.65
|
| Purchase Of Intangibles |
|
0.00
+100.00%
|
-0.04
+97.76%
|
-1.65
|
| Financing Cash Flow |
|
-6.22
-107.02%
|
88.56
-33.71%
|
133.58
|
| Cash Flow From Continuing Financing Activities |
|
-6.22
-107.02%
|
88.56
-33.71%
|
133.58
|
| Net Issuance Payments Of Debt |
|
-6.42
-388.96%
|
-1.31
-107.80%
|
16.84
|
| Issuance Of Debt |
|
0.00
|
0.00
-100.00%
|
17.50
|
| Repayment Of Debt |
|
-6.42
-388.96%
|
-1.31
-100.15%
|
-0.66
|
| Long Term Debt Issuance |
|
0.00
|
0.00
-100.00%
|
17.50
|
| Long Term Debt Payments |
|
-6.42
-388.96%
|
-1.31
-100.15%
|
-0.66
|
| Net Long Term Debt Issuance |
|
-6.42
-388.96%
|
-1.31
-107.80%
|
16.84
|
| Net Common Stock Issuance |
|
0.23
-99.75%
|
95.91
-22.94%
|
124.46
|
| Net Other Financing Charges |
|
-0.04
+99.42%
|
-6.04
+21.83%
|
-7.72
|
| Changes In Cash |
|
-152.55
-1321.70%
|
-10.73
-124.87%
|
43.14
|
| Effect Of Exchange Rate Changes |
|
0.79
-76.64%
|
3.39
-55.66%
|
7.64
|
| Beginning Cash Position |
|
190.29
-3.72%
|
197.63
+34.58%
|
146.85
|
| End Cash Position |
|
38.53
-79.75%
|
190.29
-3.72%
|
197.63
|
| Free Cash Flow |
|
-114.00
-7.96%
|
-105.59
-16.75%
|
-90.44
|
| Common Stock Issuance |
|
0.23
-99.75%
|
95.91
-22.94%
|
124.46
|
| Interest Paid CFO |
|
-1.39
-9.08%
|
-1.28
-41.10%
|
-0.91
|
| Interest Received CFO |
|
1.74
+209.04%
|
0.56
|
0.00
|
| Issuance Of Capital Stock |
|
0.23
-99.75%
|
95.91
-22.94%
|
124.46
|
| Sale Of Business |
|
0.98
|
0.00
|
0.00
|
| Taxes Refund Paid |
|
-0.00
-50.00%
|
-0.00
+0.00%
|
-0.00
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|